Apr 24,2024
Mumbai: Lupin Limited announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its Aurangabad manufacturing facility.
The inspection was conducted from March 6–15, 2024. The US FDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI).
“We are pleased to receive the EIR with VAI status from the US FDA as an outcome of the recent inspection of our Aurangabad facility. It is a testament to our commitment to consistently upholding the highest standards of compliance and providing high-quality healthcare solutions to patients worldwide,” said Nilesh Gupta, Managing Director, Lupin.
Source: Pharma
- Advertisement -
To Sponser Contact Us
To Sponser Contact Us